CiRC Biosciences is focused on developing regenerative medicines aimed at preventing and restoring vision loss associated with degenerative retinal diseases, specifically advanced retinitis pigmentosa and dry age-related macular degeneration. These conditions can lead to irreversible blindness, and the company's innovative approach seeks to address these challenges through scientific advancements. The technologies being developed have potential applications that extend beyond ophthalmology, indicating a broader impact on regenerative medicine.

The company's commitment to utilizing science in their mission underscores their goal of improving patient outcomes and quality of life for those affected by vision loss. By harnessing cutting-edge research and technology, CiRC Biosciences aims to pioneer solutions that not only target specific eye diseases but also contribute to advancements in various medical fields. This holistic approach reflects their vision of leveraging scientific progress to combat significant health challenges.

United States

CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).

CiRC Biosciences

Company Details